RNS Number : 7331W
GSK PLC
11 February 2025
 

GSK plc (the 'Company')


Transaction notification


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

 

 

The vesting of Ordinary Shares awarded in 2020 under the Company's 2017 Performance Share Plan and subject to an additional vesting period of two years from the normal vesting date  

 

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

256,706.434






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2025-02-10

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2020 under the Company's 2017 Performance Share Plan and subject to an additional vesting period of two years from the normal vesting date 

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£14.5319

.

120,653






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2025-02-10

f)

Place of the transaction

 

London Stock Exchange (XLON)



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, GSK Global Health

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Following the vesting on 10 February 2025 of 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Deborah Waterhouse will receive a cash payment of £349,569.20 less applicable tax withholding in respect of 23,853.238 notional Ordinary Shares.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£14.655

23,853.238






d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2025-02-10

f)

Place of the transaction

 

N/A


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Following the vesting on 10 February 2025 of 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Regis Simard will receive a cash payment of £174,784.60 less applicable tax withholding in respect of 11,926.619 notional Ordinary Shares.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£14.655

11,926.619






d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2025-02-10

f)

Place of the transaction

 

N/A


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Luke Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Following the vesting on 10 February 2025 of 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Luke Miels will receive a cash payment of £349,569.20 less applicable tax withholding in respect of 23,853.238 notional Ordinary Shares.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£14.655

23,853.238






d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2025-02-10

f)

Place of the transaction

 

N/A

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFEFIFEISEEE
Gsk (LSE:GSK)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Gsk Charts.